Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1130015.RA8COXC443Pf-IwqaDD-WAl3tNbEQT1-2bhxVz04wzELQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1130015.RA8COXC443Pf-IwqaDD-WAl3tNbEQT1-2bhxVz04wzELQ130_assertion type Assertion NP1130015.RA8COXC443Pf-IwqaDD-WAl3tNbEQT1-2bhxVz04wzELQ130_head.
- NP1130015.RA8COXC443Pf-IwqaDD-WAl3tNbEQT1-2bhxVz04wzELQ130_assertion description "[In the present study, we treated 161 newly diagnosed DLBCL patients with cyclophosphamide, epirubicin, vincristine, and prednisolone (CEOP) regimen with or without rituximab, and retrospectively investigated DLBCL sub-classifications combined with assessment of B cell lymphoma 2 (Bcl-2) expression level for their utility in the prediction of clinical efficacy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1130015.RA8COXC443Pf-IwqaDD-WAl3tNbEQT1-2bhxVz04wzELQ130_provenance.
- NP1130015.RA8COXC443Pf-IwqaDD-WAl3tNbEQT1-2bhxVz04wzELQ130_assertion evidence source_evidence_literature NP1130015.RA8COXC443Pf-IwqaDD-WAl3tNbEQT1-2bhxVz04wzELQ130_provenance.
- NP1130015.RA8COXC443Pf-IwqaDD-WAl3tNbEQT1-2bhxVz04wzELQ130_assertion SIO_000772 24258714 NP1130015.RA8COXC443Pf-IwqaDD-WAl3tNbEQT1-2bhxVz04wzELQ130_provenance.
- NP1130015.RA8COXC443Pf-IwqaDD-WAl3tNbEQT1-2bhxVz04wzELQ130_assertion wasDerivedFrom befree-2016 NP1130015.RA8COXC443Pf-IwqaDD-WAl3tNbEQT1-2bhxVz04wzELQ130_provenance.
- NP1130015.RA8COXC443Pf-IwqaDD-WAl3tNbEQT1-2bhxVz04wzELQ130_assertion wasGeneratedBy ECO_0000203 NP1130015.RA8COXC443Pf-IwqaDD-WAl3tNbEQT1-2bhxVz04wzELQ130_provenance.